Pauline Romanet

Dr. Pauline Romanet


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Emerging Infectious Diseases
Verified
Journal Article
Open access
PCPhilippe Colson
Philippe Colson
PRPauline Romanet
Pauline Romanet
VMValérie Moal
Valérie Moal
PBPatrick Borentain
Patrick Borentain
RPRaj Purgus
Raj Purgus
RGRené Gérolami
René Gérolami
During January–March 2011, diagnoses of hepatitis E virus (HEV) infection increased in Marseille University hospitals in southeastern France. HEV genotype 4, which is described almost exclusively in Asia, was recovered from 2 persons who ate uncooked pork liver sausage. Genetic sequences were 96.7% identical to those recently described in swine in Europe.

18 October 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
PRPauline Romanet
Pauline Romanet
AMAmira Mohamed
Amira Mohamed
SGSophie Giraud
Sophie Giraud
MOMarie-Françoise Odou
Marie-Françoise Odou
MNMarie-Odile North
Marie-Odile North
ABAnne Barlier
Anne Barlier
Context Multiple Endocrine Neoplasia type 1 (MEN1) is an autosomal dominant disease caused by mutations in the MEN1 gene characterized by a broad spectrum of clinical manifestations, of which the most frequent are primary hyperparathyroidism, pituitary adenomas, and neuroendocrine tumors. Objective The aim of this work is to facilitate interpretation of variants and improve the genetic counseling and medical care of MEN1-patients’ families. Design, Setting, and Patients The TENGEN network (French oncogenetics network of neuroendocrine tumors) has interpreted and collected all allelic variants and clinical characteristics of the MEN1-positive patients identified through genetic testing performed in the French population from 1997 to 2015. They were registered in a locus-specific database called the UMD-MEN1 database (www.umd.be/MEN1/). Main Outcomes variant classification, age-related penetrance, odds ratio. Results Three hundred seventy distinct variants reported in 1,676 patients, including 181 unpublished variants, have currently been registered. This database analysis pointed out the low frequency of benign or likely benign missense variants in MEN1 (only 6.6%). Eight families (1.9%) presented a familial isolated hyperparathyroidism and harbored the same mutation found in authentic MEN1-families. An association exists between large rearrangements and an earlier onset of the disease, whereas no difference was observed between truncating and non-truncating variants. Conclusion UMD-MEN1 database provides an exhaustive overview of the MEN1 variants present in the French population. For each variant, a classification is publicly available. Clinical data collections allow the determination of genotype-phenotype correlation and age-related penetrance of lesions in the cohort.

1 December 2017 in Thyroid®
Verified
Journal Article
Closed access
MLMaylis Lebeault
Maylis Lebeault
SPStéphane Pinson
Stéphane Pinson
MGMarine Guillaud-Bataille
Marine Guillaud-Bataille
ARAnne-Paule ROQUEPLO
Anne-Paule ROQUEPLO
ACAlain Carrie
Alain Carrie
DPDelphine PRUNIER
Delphine PRUNIER
Background: The presence of single nucleotide polymorphisms (SNPs) in the REarranged during Transfection (RET) gene has been investigated with regard to their potential role in the development or progression of medullary thyroid cancer or pheochromocytomas (PHEO) in patients with the multiple endocrine neoplasia type 2 (MEN2) syndrome. The aim of this study was to evaluate the spectrum of RET variants in France between 2003 and 2013, and to evaluate the impact of SNPs on the MEN2 A phenotype. Methods: In this retrospective cohort study, RET variants were screened in 5109 index cases, and RET pathogenic variants were screened in 2214 relatives. Exons 5, 8, 10, 11, 13, 14, 15, and 16 were characterized by Sanger sequencing. RET pathogenic variants, RET variants with unknown functional significance (VUS), and four RET SNP variants—G691S (rs1799939), L769L (rs1800861), S836S (rs1800862), and S904S (rs1800863)—were characterized and are reported in index cases. In silico analysis and classification following the recommendation of the American College of Medical Genetics and Genomics was performed for RET VUS. Each patient's age at the time of diagnosis, sex, and the endocrine neoplasias present at molecular diagnosis were recorded. Results: Twenty-six single VUS in RET without any well-defined risk profiles were found in 33 patients. Nine of these were considered probably pathogenic, 11 of uncertain significance, and six as probably benign. Three double pathogenic variants found in three patients were classified as pathogenic. A study of the entire cohort showed that patients carrying pathogenic variants or VUS in RET together with PHEO were diagnosed earlier than the others. The presence of the G691S SNP, or a combination of SNPs, increased the risk of developing PHEO but did not modify the date of the diagnosis. No association was found between SNPs and medullary thyroid cancer or hyperparathyroidism. Conclusions: The findings propose a classification of 15 of the 26 VUS in RET without any well-defined risk profiles and suggest that the G691S SNP, or a combination of SNPs, may be associated with the development of PHEO.

30 January 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
BCBenjamin Chevalier
Benjamin Chevalier
LCLucie Coppin
Lucie Coppin
PRPauline Romanet
Pauline Romanet
TCThomas Cuny
Thomas Cuny
JMJean-Christophe Maïza
Jean-Christophe Maïza
MOMarie Françoise Odou
Marie Françoise Odou
Context Germline CDKN1B variants predispose patients to multiple endocrine neoplasia type 4 (MEN4), a rare MEN1-like syndrome, with <100 reported cases since its discovery in 2006. Although CDKN1B mutations are frequently suggested to explain cases of genetically-negative MEN1, the prevalence and phenotype of MEN4 patients is poorly known, and genetic counseling is unclear. Objective To evaluate the prevalence of MEN4 in MEN1-suspected patients and characterize the phenotype of MEN4 patients. Design Retrospective observational nationwide study. Narrative review of literature and variant class reassessment. Patients We included all adult patients with class 3/4/5 CDKN1B variants identified by the laboratories from the French TENGEN network between 2015 and 2022 through germline genetic testing for MEN1 suspicion. After class reassessment, we compared the phenotype of symptomatic patients with class 4/5 CDKN1B variants, i.e. with genetically-confirmed MEN4 diagnosis, in our series and in literature with 66 matched MEN1 patients from the UMD-MEN1 database. Results From 5600 MEN1-suspected patients analyzed, four patients with class 4/5 CDKN1B variant were found (0.07%). They presented with multiple duodenal NET, PHPT and adrenal nodule, isolated PHPT, PHPT and pNET. We listed 29 patients with CDKN1B class 4/5 variants from literature. Compared to matched MEN1 patients, MEN4 patients presented lower NET incidence and older age at PHPT diagnosis. Conclusion The prevalence of MEN4 is low. PHPT and PA represent the main associated lesions, NETs are rare. Our results suggest a milder and later phenotype than in MEN1. Our observations will help to improve genetic counseling and management of MEN4 families.

16 September 2017 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
VAVincent Amodru
Vincent Amodru
CGCarole Guerin
Carole Guerin
SDSarkis Delcourt
Sarkis Delcourt
PRPauline Romanet
Pauline Romanet
ALAnderson Loundou
Anderson Loundou
DTDavid Taïeb
David Taïeb

12 November 2016 in Endocrine Pathology
Verified
Journal Article
Closed access
PDF file
PRPauline Romanet
Pauline Romanet
CGCarole Guerin
Carole Guerin
PPPascal Pedini
Pascal Pedini
WEWassim Essamet
Wassim Essamet
FCFrederic Castinetti
Frederic Castinetti
DTDavid Taïeb
David Taïeb